section name header

Evidence summaries

Pharmacological Interventions for Uraemic Pruritus in Adult Palliative Care Patients

Gabapentin, cromolyn sodium, and nalfurafine appear to be more effective than placebo for itch associated with chronic kidney disease. Level of evidence: "B"

The quality of evidence is downgraded by study limitations (unclear allocation concealment and blinding).

Summary

A Cochrane review [Abstract] 1 included 50 studies with a total of 1 916 adult subjects with 39 different treatments for pruritus in 4 different patient groups: uraemic pruritus (n=1 574), cholestatic pruritus caused by hepatobiliary diseases (n=276), pruritus associated with malignancies (n=26), and pruritus as a symptom associated with HIV (n=40). This evidence summary concerns uraemic pruritus (UP).

Gabapentin (VAS from 0 to 10: MD 5.91, 95% CI 6.87 to 4.96; 2 studies, n=118) and cromolyn sodium (MD -2.94, 95% CI 4.04 to 1.83; 2 studies, n=100) were more effective than placebo. The κ-opioid receptor agonist nalfurafine showed a small improvement of UP (VAS 0 to 10: MD 0.95, 95% CI 1.32 to 0.58; 3 studies, n=422) and only few adverse events compared to placebo. One study (n=24) showed complete improvement in 58.3% of participants treated with doxepin, and this was significantly higher than improvements with placebo (P < 0.001). Leukotriene receptor antagonist montelukast reduced pruritus by 35% (95% CI 9.5 to 62.5) compared to a reduction of 7% (95% CI 0.5 to 15.9) with placebo (P = 0.002) according to 1 small study (n=16). Also erythropoietin, thalidomide, and activated oral charcoal seemed to have a positive effect on UP. Three naltrexone studies focused on UP with conflicting results. One study (n=100) compared turmeric (500 mg) and placebo capsules 3 times a day for 8 weeks, and found that reduction of pruritus was greater in the turmeric than the placebo group (P < 0.001).

Seven studies investigated the effect of topical agents on UP. Whereas tacrolimus ointment was not more effective than the vehicle in relieving UP, pramoxine lotion tended to reduce pruritus to a greater degree than the control lotion. Four studies compared the efficacy of topical capsaicin. A meta-analysis was possible for 2 studies, and the mean pruritus in the intervention group was 1.02 standard deviations lower (1.35 lower to 0.68 lower) compared to vehicle ( 2 studies, n=112). A common minor adverse event of topical capsaicin was a transient burning sensation and local erythaema with initial application, and the risk for at least one adverse event per participant was considerably increased.

Clinical comments

Note

Date of latest search:

References

  • Siemens W, Xander C, Meerpohl JJ et al. Pharmacological interventions for pruritus in adult palliative care patients. Cochrane Database Syst Rev 2016;(11):CD008320. [PubMed]

Primary/Secondary Keywords